|
| 36528491 | Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors. | Cancer Commun (Lond) | 2023 |
| 37538150 | Cell-free DNA in the management of prostate cancer: Current status and future prospective. | Asian J Urol | 2023 |
| 37408308 | LIGHT/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment. | Mol Ther | 2023 |
| 37340527 | Utilizing Ubiquitination Patterns to Predict Prostate Cancer Prognosis and Devise a Therapeutic Response. | Arch Esp Urol | 2023 |
| 37070788 | Robotic-assisted versus laparoscopic radical prostatectomy for prostate cancer: the first separate systematic review and meta-analysis of randomised controlled trials and non-randomised studies. | Int J Surg | 2023 |
| 37294106 | Advances in landscape and related therapeutic targets of the prostate tumor microenvironment. | Acta Biochim Biophys Sin (Shanghai) | 2023 |
| 36920562 | Long non-coding RNA ENST00000503625 is a potential prognostic biomarker and metastasis suppressor gene in prostate cancer. | J Cancer Res Clin Oncol | 2023 |
| 36580231 | Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial. | Front Med | 2023 |
| 36646329 | Associations of phthalates with prostate cancer among the US population. | Reprod Toxicol | 2023 |
| 36776826 | Exploring the potential mechanisms of impairment on genitourinary system associated with coronavirus disease 2019 infection: Bioinformatics and molecular simulation analyses. | Asian J Urol | 2023 |
| 34740924 | Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy. | Clin Cancer Res | 2022 |
| 35793110 | Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial. | JAMA Surg | 2022 |
| 35359369 | CRMP4 CpG Hypermethylation Predicts Upgrading to Gleason Score â¿¥ 8 in Prostate Cancer. | Front Oncol | 2022 |
| 35750683 | Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. | Signal Transduct Target Ther | 2022 |
| 35972052 | Glycolytic potential enhanced by blockade of pyruvate influx into mitochondria sensitizes prostate cancer to detection and radiotherapy. | Cancer Biol Med | 2022 |
| 36339430 | A combined signature of glycolysis and immune landscape predicts prognosis and therapeutic response in prostate cancer. | Front Endocrinol (Lausanne) | 2022 |
| 36033474 | Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone. | Front Oncol | 2022 |
| 35980734 | Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial. | Cancer Control | 2022 |
| 36386533 | Extraperitoneal tissue retraction technique: An effective assistant of extraperitoneal pure single-port robotic-assisted radical prostatectomy with the da Vinci Si surgical system. | Front Surg | 2022 |
| 35325307 | Super-veil nerve-sparing extraperitoneal pure single-port robotic-assisted radical prostatectomy on da Vinci Si robotic system. | World J Urol | 2022 |
| 35233061 | OTUD6A promotes prostate tumorigenesis via deubiquitinating Brg1 and AR. | Commun Biol | 2022 |
| 33420488 | Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. | Nat Cell Biol | 2021 |
| 33741908 | CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer. | Nat Commun | 2021 |
| 33596421 | An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors. | Cell Rep | 2021 |
| 33558684 | SEMA3A-mediated crosstalk between prostate cancer cells and tumor-associated macrophages promotes androgen deprivation therapy resistance. | Cell Mol Immunol | 2021 |
| 34858837 | A Multicenter Single-Arm Objective Performance Criteria Trial to Determine the Efficacy and Safety of High-Frequency Irreversible Electroporation as Primary Treatment for Localized Prostate Cancer: A Study Protocol. | Front Oncol | 2021 |
| 34353330 | SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions. | Mol Cancer | 2021 |
| 34101624 | FOXA1 overexpression suppresses interferon signaling and immune response in cancer. | J Clin Invest | 2021 |
| 33283987 | Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer. | EMBO Mol Med | 2021 |
| 33282690 | SARS-CoV-2 effects in the genitourinary system and prospects of sex hormone therapy. | Asian J Urol | 2021 |
| 31107971 | The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA. | Int J Cancer | 2020 |
| 32002708 | Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain. | Cell Biol Toxicol | 2020 |
| 33443940 | Initial experience on extraperitoneal single-port robotic-assisted radical prostatectomy. | Chin Med J (Engl) | 2020 |
| 33177848 | Multiple Expression Assessments of ACE2 and TMPRSS2 SARS-CoV-2 Entry Molecules in the Urinary Tract and Their Associations with Clinical Manifestations of COVID-19. | Infect Drug Resist | 2020 |
| 33148738 | Assessing the safety and feasibility of neoadjuvant hormone and radiation therapy followed by robot-assisted radical prostatectomy for treating locally advanced prostate cancer: protocol for an open-label, dose-escalation, single-centre, phase I clinical trial. | BMJ Open | 2020 |
| 32801300 | LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression. | Cell Death Dis | 2020 |
| 32592689 | Novel Long Non-coding RNA lncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression. | Mol Ther | 2020 |
| 32238934 | A genomic and epigenomic atlas of prostate cancer in Asian populations. | Nature | 2020 |
| 32460179 | Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer. | Eur J Cancer | 2020 |
| 32289797 | Robotic Perineal Radical Prostatectomy: Initial Experience with the da Vinci Si Robotic System. | Urol Int | 2020 |
| 31187780 | Prostate cancer risk prediction models in Eastern Asian populations: current status, racial difference, and future directions. | Asian J Androl | 2020 |
| 30595538 | SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. | Dev Cell | 2019 |
| 31771591 | Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly. | Mol Cancer | 2019 |
| 31270456 | Author Correction: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. | Nature | 2019 |
| 31297322 | Single-port transperitoneal robotic-assisted laparoscopic radical prostatectomy (spRALP): Initial experience. | Asian J Urol | 2019 |
| 30925930 | Microvesicles and chemokines in tumor microenvironment: mediators of intercellular communications in tumor progression. | Mol Cancer | 2019 |
| 30777011 | Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. | BMC Genomics | 2019 |
| 31064850 | Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer. | Cancer Res | 2019 |
| 30770901 | Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer. | Oncogene | 2019 |
| 30853808 | Efficacy and safety of combined androgen blockade with antiandrogen for advanced prostate cancer. | Curr Oncol | 2019 |